Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Biomarin Pharmaceutical Inc

Healthcare US BMRN

56.47USD
1.81(3.31%)

Last update at 2026-06-04T20:00:00Z

Day Range

55.1157.05
LowHigh

52 Week Range

50.7666.28
LowHigh

Fundamentals

  • Previous Close 54.66
  • Market Cap10504.70M
  • Volume2076169
  • P/E Ratio30.51
  • Dividend Yield-%
  • EBITDA722.89M
  • Revenue TTM3221.25M
  • Revenue Per Share TTM16.80
  • Gross Profit TTM 1701.09M
  • Diluted EPS TTM1.79

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 482.48M 541.76M 188.56M 149.58M -75.35000M
Minority interest - - - - -
Net income 348.90M 426.86M 167.65M 141.56M -64.08000M
Selling general administrative 1153.02M 532.30M 404.00M 403.71M 354.30M
Selling and marketing expenses 124.00M 476.70M 488.40M 450.30M 405.10M
Gross profit 2484.43M 2273.68M 1887.16M 1612.37M 1375.76M
Reconciled depreciation 79.56M 96.43M 102.08M 101.97M 108.04M
Ebit 493.38M 554.10M 202.39M 57.55M -60.01300M
Ebitda 572.94M 650.53M 306.77M 159.51M 48.03M
Depreciation and amortization 79.56M 96.43M 104.39M 101.97M 108.04M
Non operating income net other - - - - 10.48M
Operating income 533.48M 484.21M 185.77M 57.55M -60.01300M
Other operating expenses 2687.78M 2369.70M 2233.45M 2054.48M 1928.62M
Interest expense 10.90M 12.67M 17.34M 15.97M 15.34M
Tax provision 133.58M 114.90M 4.66M 8.02M -11.27000M
Interest income 74.90M 74.88M 49.01M 18.03M 10.48M
Net interest income 64.00M 62.15M 34.14M 2.06M -4.85500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 133.58M 114.90M 20.92M 8.02M -11.27000M
Total revenue 3221.25M 2853.91M 2419.23M 2096.04M 1846.28M
Total operating expenses 1950.95M 1789.47M 1701.39M 1570.81M 1458.10M
Cost of revenue 736.83M 580.24M 532.06M 483.67M 470.51M
Total other income expense net -50.99800M 57.55M 2.79M 92.03M -15.33700M
Discontinued operations - - - - -
Net income from continuing ops 348.90M 426.86M 147.02M 141.56M -64.08000M
Net income applicable to common shares - - - 141.56M -64.08000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7594.02M 6988.94M 6841.60M 6375.07M 6003.32M
Intangible assets 213.84M 255.28M 294.70M 338.57M 388.65M
Earning assets - - - - -
Other current assets 185.78M 201.53M 141.39M 104.52M 110.44M
Total liab 1507.02M 1330.95M 1890.05M 1771.92M 1732.59M
Total stockholder equity 6087.00M 5657.99M 4951.55M 4603.16M 4270.74M
Deferred long term liab - - - - -
Other current liab 437.58M 334.58M 354.24M 346.56M 329.40M
Common stock 0.19M 0.19M 0.19M 0.19M 0.18M
Capital stock 0.19M 0.19M 0.19M 0.19M 0.18M
Retained earnings 154.21M -194.69500M -621.55400M -789.19900M -925.68900M
Other liab - - - 73.50M 113.69M
Good will 196.20M 196.20M 196.20M 196.20M 196.20M
Other assets - - - 1604.19M 1600.84M
Cash 1311.68M 942.84M 755.13M 724.53M 587.28M
Cash and equivalents - - - - -
Total current liabilities 759.03M 606.99M 1177.02M 588.88M 539.82M
Current deferred revenue - 1.37M 4.62M 0.71M 6.96M
Net debt -668.80600M -293.37600M 378.75M 358.49M 491.80M
Short term debt 8.69M 23.07M 502.66M 10.38M 10.46M
Short long term debt - - 493.88M - -
Short long term debt total 642.87M 649.47M 1133.88M 1083.02M 1079.08M
Other stockholder equity 5956.58M 5790.84M 5611.56M 5396.04M 5181.81M
Property plant equipment - - - 1114.32M 1035.46M
Total current assets 3953.49M 3232.43M 2956.09M 2751.46M 2274.39M
Long term investments 492.24M 521.24M 611.13M 333.83M 507.79M
Net tangible assets - - - 4068.39M 3685.89M
Short term investments 248.93M 194.86M 318.68M 567.01M 426.60M
Net receivables 908.21M 660.53M 633.70M 461.32M 373.40M
Long term debt 597.18M 595.14M 593.10M 1083.02M 1079.08M
Inventory 1298.88M 1232.65M 1107.18M 894.08M 776.67M
Accounts payable 312.77M 235.40M 315.51M 231.24M 193.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -23.98100M 61.65M -38.64800M -3.86700M 14.43M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.18M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -925.68900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 277.05M 251.39M 121.22M 176.24M 151.76M
Deferred long term asset charges - - - - -
Non current assets total 3640.53M 3756.51M 3885.51M 3623.62M 3728.94M
Capital lease obligations 8.69M 7.57M 8.78M 10.38M 10.46M
Long term debt total - - - - 1079.08M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -18.07400M 136.49M -100.99100M -20.02900M -366.31300M
Change to liabilities - - - 59.02M 12.35M
Total cashflows from investing activities -414.24200M 136.49M -111.24400M -20.02900M -366.31300M
Net borrowings 0.00000M -494.98700M 0.00000M -2.60500M -3.03900M
Total cash from financing activities -42.39400M -526.44700M -18.72700M -18.65000M -0.04800M
Change to operating activities - - - -5.10400M 19.83M
Net income 348.90M 426.86M 167.65M 141.56M -64.08000M
Change in cash 368.84M 187.72M 30.60M 137.25M -61.88200M
Begin period cash flow 942.84M 755.13M 724.53M 587.28M 649.16M
End period cash flow 1311.68M 942.84M 755.13M 724.53M 587.28M
Total cash from operating activities 827.99M 572.84M 159.26M 175.90M 304.54M
Issuance of capital stock - - - - -
Depreciation 79.56M 96.43M 104.39M 101.97M 108.04M
Other cashflows from investing activities -7.93700M -0.85300M -10.92000M 103.33M -24.64100M
Dividends paid - - - - -
Change to inventory 119.21M -63.53000M -157.05800M -68.26400M -35.06000M
Change to account receivables -228.05400M -57.90900M -190.43500M -82.03300M 65.57M
Sale purchase of stock - -77.56000M -76.31900M 0.00000M 49.19M
Other cashflows from financing activities -42.39400M -31.46000M -85.79400M -16.04500M 2.99M
Change to netincome - - - 28.75M 185.24M
Capital expenditures 103.04M 97.42M 96.69M 131.54M 119.22M
Change receivables - - - - 65.57M
Cash flows other operating - - - - 23.17M
Exchange rate changes - - - - -0.05700M
Cash and cash equivalents changes - - - - -61.88200M
Change in working capital -108.68200M -216.39600M -336.53900M -96.38300M 66.03M
Stock based compensation 181.41M 201.57M 207.10M 196.31M 197.26M
Other non cash items 278.07M 8.29M 61.65M -115.46600M 12.89M
Free cash flow 724.96M 475.42M 62.57M 44.36M 185.31M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BMRN
Biomarin Pharmaceutical Inc		 1.81 3.31% 56.47 30.51 10.81 3.26 1.73 2.96 16.67
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Biomarin Pharmaceutical Inc

770 Lindaro Street, San Rafael, CA, United States, 94901

Key Executives

Name Title Year Born
Mr. Jean-Jacques Bienaime M.B.A., MBA Chairman & CEO 1953
Mr. Brian R. Mueller Exec. VP of Fin. & CFO 1974
Dr. C. Greg Guyer Ph.D. CTO and Exec. VP of Global Manufacturing & Technical Operations 1962
Mr. Jeffrey Robert Ajer Exec. VP & Chief Commercial Officer 1962
Dr. Henry J. Fuchs M.D., Ph.D. Pres of Worldwide R&D 1958
Ms. Erin Burkhart Group VP & Chief Accounting Officer NA
Traci McCarty VP of Investor Relations NA
Mr. George Eric Davis Exec. VP, Gen. Counsel & Sec. 1971
Mr. Philip Lo Scalzo Sr. VP & Chief Compliance Officer NA
Ms. Humaira Serajuddin Sr. VP & Chief Marketing Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.